Enhanced Group Inc. (ENHA) Adds Six Peptides to Its Telehealth Platform

What happened

Enhanced Group Inc. added six peptides to its Live Enhanced telehealth platform, which already offered GHK-Cu and Sermorelin. Access is prescription-only after evaluation by a licensed clinician, and the release gave no revenue or uptake estimates.

Confirmed

Global impact / market context

The update widens the company's prescription-only telehealth menu, but it discloses no revenue or customer numbers, so investors cannot yet size the financial benefit. Real impact would depend on customer uptake and on whether regulators restrict which peptides can be offered.

Analyst inference

Telehealth firms are adding products to attract subscribers, but peptide sales face rules that limit access to consumers with a clinician's prescription. An advisory committee is expected to review additional peptides in February 2027, which could change what platforms like Live Enhanced can sell.

Analyst inference

What to watch

1. Access to the six new peptides requires evaluation by a licensed clinician and a prescription, which limits the offering to eligible consumers rather than open direct purchase. Confirmed
2. The company could later disclose subscriber numbers, prescription volumes, or peptide revenue, which would show whether the expanded menu is actually drawing paying customers. Proposed
3. Ongoing rulemaking on the 503A list, a set of ingredients compounders may use, and the February 2027 advisory committee review could affect peptide availability and platform sales. Analyst inference

Evidence

• Original source link unavailable